Last reviewed 2026-04-20 · How we verify

Omnipaque

At a glance

Approved indications

No approved indications tracked.

Boxed warnings

• WARNING: RISKS ASSOCIATED WITH INTRATHECAL ADMINISTRATION OF OMNIPAQUE INJECTION 140 mg IODINE/mL and 350 mg IODINE/mL Use only the OMNIPAQUE iodine concentrations and presentations recommended for intrathecal procedure [see Dosage and Administration (2.2 , 2.8) ]. Intrathecal administration of OMNIPAQUE of a wrong iodine concentration, even if inadvertent, may cause death, convulsions, seizures, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, rhabdomyol

Common side effects

• Vomiting
• Nausea

Serious adverse events

• Cerebral infarction
• Transient ischemic attack
• Convulsion
• Cardiac failure
• Asystole
• Ventricular tachycardia
• 2:1 heart block
• Apnea
• Hemiparesis
• Motor and speech dysfunction

Key clinical trials

• Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol (PHASE1)
• Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI) (PHASE4)
• Evolution of Post-Stroke Shoulder Pain With a Capsular Pattern With Physiotherapy Alone Versus Coupled With Mild Arthrographic Distension With Cortisone (PHASE4)
• Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3 (PHASE4)
• Contrast and Anesthetic Level With Lumbar Erector Spinae Plan (ESP) Block (NA)
• Morphine Clearance and Glomerular Filtration in Sickle Cell Patients in Crisis in Intensive Care (NA)
• Oral Iohexol in the Management of Chylous Ascites After After Retroperitoneal or Extended Lymphadenectomy (PHASE2)
• The Practicality and Utility of Measured vs Estimated GFR in adCKD

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.